Novo Nordisk
Investments
27Portfolio Exits
10Partners & Customers
10Service Providers
1About Novo Nordisk
Novo Nordisk operates as a global healthcare company. It focuses on defeating serious chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. The company's main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease. It primarily serves the healthcare industry. It was founded in 1989 and is based in Bagsvaerd, Denmark.
Expert Collections containing Novo Nordisk
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Novo Nordisk in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
Conference Exhibitors
5,302 items
Latest Novo Nordisk News
Dec 27, 2023
December 27, 2023 at 09:32 am EST Share NEW YORK, Dec. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, MU, NVO, ZM, and HUT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock. Stock Report - Measures a stock's suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street's opinion including a 12-month price forecast. AAPL: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=AAPL&prnumber=202312273 MU: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=MU&prnumber=202312273 NVO: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=NVO&prnumber=202312273 ZM: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=ZM&prnumber=202312273 HUT: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=HUT&prnumber=202312273 (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options. View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-apple-micron-technology-novo-nordisk-zoom-video-or-hut-8-302022792.html SOURCE InvestorsObserver
Novo Nordisk Investments
27 Investments
Novo Nordisk has made 27 investments. Their latest investment was in ElevateBio as part of their Series D on May 24, 2023.
Novo Nordisk Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/24/2023 | Series D | ElevateBio | $401M | Yes | AyurMaya Capital Management, EcoR1 Capital, EDBI, Emerson Collective, F2 Ventures, Fidelity Investments, Invus Group, ITOCHU, Lee Family Office, Matrix Capital, Matrix Capital Management, MPM Capital, Redmile Group, Samsara BioCapital, SoftBank, Surveyor Capital, Vertex Ventures, and Woodline Partners | 10 |
4/12/2023 | Convertible Note | Aspect Biosystems | $55.75M | Yes | 2 | |
12/19/2022 | Series B | Amalgam Rx | $17.37M | Yes | 2 | |
2/18/2022 | Series C | |||||
3/16/2021 | Series D |
Date | 5/24/2023 | 4/12/2023 | 12/19/2022 | 2/18/2022 | 3/16/2021 |
|---|---|---|---|---|---|
Round | Series D | Convertible Note | Series B | Series C | Series D |
Company | ElevateBio | Aspect Biosystems | Amalgam Rx | ||
Amount | $401M | $55.75M | $17.37M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | AyurMaya Capital Management, EcoR1 Capital, EDBI, Emerson Collective, F2 Ventures, Fidelity Investments, Invus Group, ITOCHU, Lee Family Office, Matrix Capital, Matrix Capital Management, MPM Capital, Redmile Group, Samsara BioCapital, SoftBank, Surveyor Capital, Vertex Ventures, and Woodline Partners | ||||
Sources | 10 | 2 | 2 |
Novo Nordisk Portfolio Exits
10 Portfolio Exits
Novo Nordisk has 10 portfolio exits. Their latest portfolio exit was Disc Medicine on December 29, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/29/2022 | Reverse Merger | 4 | |||
7/17/2020 | IPO | Public | 3 | ||
8/1/2019 | IPO | Public | 3 | ||
Date | 12/29/2022 | 7/17/2020 | 8/1/2019 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 4 | 3 | 3 |
Novo Nordisk Acquisitions
15 Acquisitions
Novo Nordisk acquired 15 companies. Their latest acquisition was Embark Biotech on August 30, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
8/30/2023 | Acquired | 3 | ||||
8/10/2023 | Series C | $109.4M | Acquired | 4 | ||
8/4/2023 | Corporate Majority - P2P | 3 | ||||
9/1/2022 | Series D | |||||
12/28/2021 | Series C |
Date | 8/30/2023 | 8/10/2023 | 8/4/2023 | 9/1/2022 | 12/28/2021 |
|---|---|---|---|---|---|
Investment Stage | Series C | Series D | Series C | ||
Companies | |||||
Valuation | |||||
Total Funding | $109.4M | ||||
Note | Acquired | Acquired | Corporate Majority - P2P | ||
Sources | 3 | 4 | 3 |
Novo Nordisk Partners & Customers
10 Partners and customers
Novo Nordisk has 10 strategic partners and customers. Novo Nordisk recently partnered with Genevant on November 11, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
11/6/2023 | Partner | United States | 1 | ||
10/19/2023 | Partner | United States | GE HealthCare Technologies Inc. today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound . | 5 | |
10/18/2023 | Partner | United States, United Kingdom, and Switzerland | 18 , 2023 -- Meharry Medical College , along with partners Regeneron ® , AstraZeneca , Novo Nordisk , and Roche , today announced the launch of the Together for CHANGE ™ initiative to create better health care and outcomes for all . | 2 | |
9/25/2023 | Partner | ||||
9/20/2023 | Vendor |
Date | 11/6/2023 | 10/19/2023 | 10/18/2023 | 9/25/2023 | 9/20/2023 |
|---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Vendor |
Business Partner | |||||
Country | United States | United States | United States, United Kingdom, and Switzerland | ||
News Snippet | GE HealthCare Technologies Inc. today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound . | 18 , 2023 -- Meharry Medical College , along with partners Regeneron ® , AstraZeneca , Novo Nordisk , and Roche , today announced the launch of the Together for CHANGE ™ initiative to create better health care and outcomes for all . | |||
Sources | 1 | 5 | 2 |
Novo Nordisk Service Providers
1 Service Provider
Novo Nordisk has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Merger | Investment Bank | Financial Advisor |
Service Provider | |
|---|---|
Associated Rounds | Merger |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
Novo Nordisk Team
43 Team Members
Novo Nordisk has 43 team members, including current Chief Executive Officer, President, Lars Fruergaard Jørgensen.
Name | Work History | Title | Status |
|---|---|---|---|
Lars Fruergaard Jørgensen | Chief Executive Officer, President | Current | |
Name | Lars Fruergaard Jørgensen | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer, President | ||||
Status | Current |
Compare Novo Nordisk to Competitors
Boehringer Ingelheim is a research-driven biopharmaceutical company. The company's main offerings include innovative therapies in areas of high unmet medical need, spanning three business areas: human pharma, animal health, and biopharmaceutical contract manufacturing. It primarily serves the pharmaceutical and healthcare industries. The company was founded in 1885 and is based in Ingelheim am Rhein, Germany.
GI Innovation is a bio-venture company that focuses on integrating basic science and translational innovation in the biologics sector. The company's main services include the development of biologics for immuno-oncology and inflammation/immunology diseases, utilizing their proprietary GI-SMART platform technology to optimize multi-targeting fusion protein therapeutics. The company primarily sells to the healthcare and pharmaceutical industries. It was founded in 2017 and is based in Seoul, South Korea.
Norstella is a company that focuses on providing solutions in the pharmaceutical industry. The company offers a range of consultancy services and solutions, helping clients navigate the complexities of the drug development life cycle, from pipeline to patient. Norstella primarily serves the pharmaceutical industry. It is based in Morrisville, Pennsylvania.
Pkvitality is a bio-wearable company that operates in the health and fitness wearable market. The company develops next-generation trackers that analyze key physiological markers by testing the skin, offering products such as a glucose monitor for diabetics and a lactate monitor for athletes. Pkvitality primarily serves the health and fitness industry. It was founded in 2017 and is based in Paris, France.
i-Health is a global consumer health and wellness company operating in the healthcare sector. The company develops, markets, and distributes branded products that support health and wellness, focusing on areas such as vaginal and urinary health, gut and immunity health for children and babies, hormonal health during menopause, and digestive health for adults. i-Health primarily serves the consumer healthcare industry. It was founded in 2012 and is based in Cromwell, Connecticut.
OraSure Technologies develops, manufactures, and markets oral-fluid collection devices using proprietary oral fluid technologies, and diagnostic products including immunoassays in vitro diagnostic tests, and other medical devices. The company was founded in 1987 and is based in Bethlehem, Pennsylvania.
Loading...